MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: Relevance to negative symptoms associated with schizophrenia?

Pharmacology Biochemistry and Behavior

Volumn 95, Issue 2, 2010, Pages 223-229

  Vardigan, Joshua D ^a   Huszar, Sarah L ^a   McNaughton, Caitlyn H ^a   Hutson, Peter H ^a   Uslaner, Jason M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anhedonia; Metabotropic glutamate receptor; Negative symptoms; NMDA; Schizophrenia

Indexed keywords

3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; CLOZAPINE; DEXTRO SERINE; DIZOCILPINE; HALOPERIDOL; NEUROLEPTIC AGENT; SUCROSE; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; MALE; MOTOR PERFORMANCE; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TASTE PREFERENCE;

ALLOSTERIC REGULATION; ANIMALS; BENZAMIDES; CLOZAPINE; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; PYRAZOLES; QUININE; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SERINE; SUCROSE;

ANIMALIA;

EID: 76949085425     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.01.010     Document Type: Article

References (65)

1. Awad H., Hubert G.W., Smith Y., Levey A.I., and Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20 (2000) 7871-7879
2. Baird J.P., Turgeon S., Wallman A., and Hulick V. Behavioral processes mediating phencyclidine-induced decreases in voluntary sucrose consumption. Pharmacol Biochem Behav 88 (2008) 272-279
3. Borison R.L. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15 (1995) 24S-29S
4. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., and Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 163 (2006) 418-425
5. Bragina L., Melone M., Fattorini G., Torres-Ramos M., Vallejo-Illarramendi A., Matute C., et al. GLT-1 down-regulation induced by clozapine in rat frontal cortex is associated with synaptophysin up-regulation. J Neurochem 99 (2006) 134-141
6. Brar J.S., Chengappa K.N., Parepally H., Sandman A.R., Kreinbrook S.B., Sheth S.A., et al. The effects of clozapine on negative symptoms in patients with schizophrenia with minimal positive symptoms. Ann Clin Psychiatry 9 (1997) 227-234
7. Coyle J.T., and Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174 (2004) 32-38
8. Darrah J.M., Stefani M.R., and Moghaddam B. Interaction of N-methyl-d-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav Pharmacol 19 (2008) 225-234
9. Doherty A.J., Palmer M.J., Henley J.M., Collingridge G.L., and Jane D.E. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36 (1997) 265-267
10. Fitzgerald L.W., Deutch A.Y., Gasic G., Heinemann S.F., and Nestler E.J. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 15 (1995) 2453-2461
11. Gemperle A., and Olpe H.R. Effects of subchronic clozapine treatment on long-term potentiation in rat prefrontal cortex. Eur Neuropsychopharmacol 14 (2004) 340-346
12. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 153 (1996) 321-330
13. Guo J.D., Wang H., Zhang Y.Q., and Zhao Z.Q. Alterations of membrane properties and effects of d-serine on NMDA-induced current in rat anterior cingulate cortex neurons after monoarthritis. Neurosci Lett 384 (2005) 245-249
14. Harvey P.D., Koren D., Reichenberg A., and Bowie C.R. Negative symptoms and cognitive deficits: what is the nature of their relationship?. Schizophr Bull 32 (2006) 250-258
15. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9 (1987) 12-35
16. Javitt D.C. Management of negative symptoms of schizophrenia. Curr Psychiatry Rep 3 (2001) 413-417
17. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
18. Johnson J.W., and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 (1987) 529-531
19. Kapur S., and Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1081-1090
20. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305 (2003) 625-631
21. Kemp J.A., and Leeson P.D. The glycine site of the NMDA receptor-five years on. Trends Pharmacol Sci 14 (1993) 20-25
22. Kirkpatrick B., and Buchanan R.W. Anhedonia and the deficit syndrome of schizophrenia. Psychiatry Res 31 (1990) 25-30
23. Kontaxakis V.P., Kollias C.T., Havaki-Kontaxaki B.J., Margariti M.M., Stamouli S.S., Petridou E., et al. Physical anhedonia in the acute phase of schizophrenia. Ann Gen Psychiatry 5 (2006) 1
24. Kotecha S.A., Jackson M.F., Al-Mahrouki A., Roder J.C., Orser B.A., and MacDonald J.F. Co-stimulation of mGluR5 and N-methyl-d-aspartate receptors is required for potentiation of excitatory synaptic transmission in hippocampal neurons. J Biol Chem 278 (2003) 27742-27749
25. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
26. Krystal J.H., Perry Jr. E.B., Gueorguieva R., Belger A., Madonick S.H., Abi-Dargham A., et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62 (2005) 985-994
27. Lindsley C.W., Wisnoski D.D., Leister W.H., O'Brien J.A., Lemaire W., Williams Jr. D.L., et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem 47 (2004) 5825-5828
28. Liu F., Grauer S., Kelley C., Navarra R., Graf R., Zhang G., et al. ADX47273: a novel metabotropic glutamate receptor 5 selective positive allosteric modulator with preclinical antipsychotic-like and pro-cognitive activities. J Pharmacol Exp Ther (2008)
29. Liu F., Zhang G., Hornby G., Vasylyev D., Bowlby M., Park K., et al. The effect of mGlu5 receptor positive allosteric modulators on signaling molecules in brain slices. Eur J Pharmacol 536 (2006) 262-268
30. Loas G., Noisette C., Legrand A., and Boyer P. Anhedonia, depression and the deficit syndrome of schizophrenia. Acta Psychiatr Scand 94 (1996) 477-479
31. Marona-Lewicka D., and Nichols D.E. The effect of selective serotonin releasing agents in the chronic mild stress model of depression in rats. Stress 2 (1997) 91-100
32. Martina M., Krasteniakov N.V., and Bergeron R. d-Serine differently modulates NMDA receptor function in rat CA1 hippocampal pyramidal cells and interneurons. J Physiol 548 (2003) 411-423
33. McBain C.J., Kleckner N.W., Wyrick S., and Dingledine R. Structural requirements for activation of the glycine coagonist site of N-methyl-d-aspartate receptors expressed in Xenopus oocytes. Mol Pharmacol 36 (1989) 556-565
34. Melone M., Vitellaro-Zuccarello L., Vallejo-Illarramendi A., Perez-Samartin A., Matute C., Cozzi A., et al. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 6 (2001) 380-386
35. Meltzer H.Y. Dimensions of outcome with clozapine. Br J Psychiatry Suppl (1992) 46-53
36. Meltzer H.Y., Matsubara S., and Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25 (1989) 390-392
37. Michal P., Lysikova M., El-Fakahany E.E., and Tucek S. Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors. Eur J Pharmacol 376 (1999) 119-125
38. Millan M.J. N-methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 179 (2005) 30-53
39. Mothet J.P., Parent A.T., Wolosker H., Brady Jr. R.O., Linden D.J., Ferris C.D., et al. d-Serine is an endogenous ligand for the glycine site of the N-methyl-d-aspartate receptor. Proc Natl Acad Sci U S A 97 (2000) 4926-4931
40. Muscat R., Papp M., and Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology (Berl) 109 (1992) 433-438
41. Natesan S., Reckless G.E., Barlow K.B., Nobrega J.N., and Kapur S. Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophr Res 105 (2008) 224-235
42. Olianas M.C., Maullu C., and Onali P. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br J Pharmacol 122 (1997) 401-408
43. Oliver M.W., Larson J., and Lynch G. Activation of the glycine site associated with the NMDA receptor is required for induction of LTP in neonatal hippocampus. Int J Dev Neurosci 8 (1990) 417-424
44. Park I.H., Kim J.J., Chun J., Jung Y.C., Seok J.H., Park H.J., et al. Medial prefrontal default-mode hypoactivity affecting trait physical anhedonia in schizophrenia. Psychiatry Res 171 (2009) 155-165
45. Purdon S.E., Malla A., Labelle A., and Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26 (2001) 137-149
46. Rollema H., Lu Y., Schmidt A.W., and Zorn S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 338 (1997) R3-R5
47. Sams-Dodd F. Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neurosci Biobehav Rev 23 (1998) 287-293
48. Schmitt A., Zink M., Petroianu G., May B., Braus D.F., and Henn F.A. Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neurosci Lett 347 (2003) 81-84
49. Schooler N.R. Negative symptoms in schizophrenia: assessment of the effect of risperidone. J Clin Psychiatry 55 (1994) 22-28 Suppl
50. Seeman P., and Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188 (1975) 1217-1219
51. Seeman P., Chau-Wong M., Tedesco J., and Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A 72 (1975) 4376-4380
52. Shimura T., Kamada Y., and Yamamoto T. Ventral tegmental lesions reduce overconsumption of normally preferred taste fluid in rats. Behav Brain Res 134 (2002) 123-130
53. Smith S.M., Uslaner J., Yao L., Mullins C., Surles N., Huszar S., et al. The behavioral and neurochemical effects of a novel d-amino acid oxidase inhibitor 4H-thieno [3,2-b] pyrrole-5-carboxylic acid (Compound 8) and d-serine. J Pharmacol Exp Ther (2008)
54. Spielewoy C, Markou A. Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology 2003;28:1106-16.
55. Steinpress R.E. The behavioral and neurochemical effects of phencyclidine in humans and animals: some implications for modeling psychosis. Behav Brain Res 74 (1996) 45-55
56. Towell A., Muscat R., and Willner P. Effects of pimozide on sucrose consumption and preference. Psychopharmacology (Berl) 92 (1987) 262-264
57. Tsai G., Yang P., Chung L.C., Lange N., and Coyle J.T. d-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44 (1998) 1081-1089
58. Turgeon S.M., and Hulick V.C. Differential effects of acute and subchronic clozapine and haloperidol on phencyclidine-induced decreases in voluntary sucrose consumption in rats. Pharmacol Biochem Behav 86 (2007) 524-530
59. Uslaner J.M., Parmentier-Batteur S., Flick R.B., Surles N.O., Lam J.S., McNaughton C.H., et al. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology (2009)
60. Vollenweider F.X., Leenders K.L., Oye I., Hell D., and Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7 (1997) 25-38
61. Willner P., Towell A., Sampson D., Sophokleous S., and Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93 (1987) 358-364
62. Yamamoto B.K., Pehek E.A., and Meltzer H.Y. Brain region effects of clozapine on amino acid and monoamine transmission. J Clin Psychiatry 55 (1994) 8-14 Suppl B
63. Yang Y., Ge W., Chen Y., Zhang Z., Shen W., Wu C., et al. Contribution of astrocytes to hippocampal long-term potentiation through release of d-serine. Proc Natl Acad Sci U S A 100 (2003) 15194-15199
64. Zeng X.P., Le F., and Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 321 (1997) 349-354
65. Zorn S.H., Jones S.B., Ward K.M., and Liston D.R. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur J Pharmacol 269 (1994) R1-R2